News
-
-
-
COMMUNIQUÉ DE PRESSE
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from VenoValve pivotal trial show sustained clinical improvement at 24 months compared to baseline. FDA decision expected in 2025 -
-
-
-
-
COMMUNIQUÉ DE PRESSE
Information regarding the total number of voting rights and shares comprising the share capital as of the date of the notice of the Mixed General Meeting on 25 June 2025
Exail Technologies discloses total voting rights and share capital info as of June 4, 2025 per Commercial Code regulation. Specializing in autonomous robotics, navigation system technologies. Listed on Euronext Paris Compartment B and OTCQX Best Market -
-
